Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Treatment monitoring of HIV-infected patients based on mechanistic models.

Prague M, Commenges D, Drylewicz J, Thiébaut R.

Biometrics. 2012 Sep;68(3):902-11. doi: 10.1111/j.1541-0420.2012.01749.x. Epub 2012 Aug 30.

PMID:
22934714
2.

[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Spanish.

PMID:
22633764
3.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
4.

Taking side effects into account for HIV medication.

Costanza V, Rivadeneira PS, Biafore FL, D'Attellis CE.

IEEE Trans Biomed Eng. 2010 Sep;57(9):2079-89. doi: 10.1109/TBME.2010.2049845. Epub 2010 May 24.

PMID:
20501345
5.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
6.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
7.

Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.

Fraser C, Ferguson NM, Ghani AC, Prins JM, Lange JM, Goudsmit J, Anderson RM, de Wolf F.

AIDS. 2000 Apr 14;14(6):659-69.

PMID:
10807189
8.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
9.

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.

García F, Plana M, Vidal C, Cruceta A, O'Brien WA, Pantaleo G, Pumarola T, Gallart T, Miró JM, Gatell JM.

AIDS. 1999 Jul 30;13(11):F79-86.

PMID:
10449278
10.

Latently infected cell activation: a way to reduce the size of the HIV reservoir?

Forde J, Volpe JM, Ciupe SM.

Bull Math Biol. 2012 Jul;74(7):1651-72. doi: 10.1007/s11538-012-9729-x. Epub 2012 May 5.

PMID:
22562387
11.

[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.

Zhonghua Yi Xue Za Zhi. 2007 Nov 13;87(42):2973-6. Chinese.

PMID:
18261327
12.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
13.

Optimal drug treatment regimens for HIV depend on adherence.

Krakovska O, Wahl LM.

J Theor Biol. 2007 Jun 7;246(3):499-509. Epub 2007 Jan 23.

PMID:
17320115
14.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
15.

Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.

Li T, Wu N, Dai Y, Qiu Z, Han Y, Xie J, Zhu T, Li Y.

Clin Infect Dis. 2011 Nov;53(9):944-51. doi: 10.1093/cid/cir552. Epub 2011 Sep 29.

PMID:
21960716
16.

Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.

Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D, Clerici M.

Blood. 2011 Sep 22;118(12):3263-72. doi: 10.1182/blood-2011-01-329060. Epub 2011 May 16.

18.

Mutation and control of the human immunodeficiency virus.

Stengel RF.

Math Biosci. 2008 Jun;213(2):93-102. doi: 10.1016/j.mbs.2008.03.002. Epub 2008 Mar 20.

PMID:
18439629
19.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
20.

The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.

García F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miró JM, Gatell JM.

AIDS. 2001 Jun 15;15(9):F29-40.

PMID:
11416735

Supplemental Content

Support Center